Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/2292—Thymosin; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents

Definitions

• the present invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies.
• Allergies are an excessive reaction to substances that are not generally dangerous to man, given that they constitute a paroxitic immunitary response compared to a normal one.
• the body's immune system normally protects us from pathogens such as bacteria, viruses or toxic substances.
• An allergy is instead the reaction of a hypersensitive immune system towards non-pathogenic organisms. It is the first exposure to an allergen which causes the allergic reaction in the individual and makes him recognise the allergen every time he comes into contact with it later. The symptoms arise in the second and all subsequent exposures and strictly depend not only on the allergen concerned, but also on the part of the body affected and on the intensity of the immunitary reaction.
• the allergen When the allergen comes into contact with an individual's immune system, it stimulates the production of antibodies which bind to cells containing histamine. It is the production of this substance that causes the typical allergic symptoms in the patient: itching, swelling of the affected tissues, hypersecretion of mucous, and muscle spasms. The severity and variety of these symptoms is strongly subjective because it depends on the individual.
• the most common allergens are food, drugs, some substances contained in cosmetics, certain metals used in jewellery or trinkets, insect bites, dust mites, pollen, moulds and pets.
• Thymosin alpha 1 (T ⁇ 1), a thymic peptide found in nature, is well known for the treatment of some viral infections both as a monotherapy and in association with IFN- ⁇ , and as an immunitary adjuvant (Goldstein A. et al., 2004 Expert Opin.Biol. Ther. 4:559-573). Other therapeutic indications are also known about thymosin alpha 1 such as in the treatment for immunodeficiency, tumours and AIDS. Thymosin alpha 1 is also known as a modulator of the biological response in the treatment of certain viral infections in association with INF- ⁇ , and as an immune adjuvant (Goldstein A. et al., 2004 Expert Opin.Biol. Ther.
• T ⁇ 1 modulates the functioning of dendritic cells (DC) through the toll-like receptor (TLR) 9, thus acting as an endogenous regulator of the inborn and adaptive immune systems (Romani L. et al., 2004, Blood 103:4232-4239). Thanks to this functional activity on DC, T ⁇ 1 has been found to be able to induce functionally active Treg both in vitro and in vivo (Romani L, Blood 2006). These studies provide the rational premises for the use of T ⁇ 1 as an inducer of functionally active Treg. In the face of a generalised and indiscriminate suppression, such as the one achieved by current corticosteroid therapies, this approach would offer the advantage of a regulation of highly selective and specific aberrant immune reactions.
• the specific object of the present invention is thus the use of T ⁇ 1 for the preparation of a medicament for the prevention and treatment of allergies in which the allergies are, for example, those caused by allergens such as substances contained in food, like ovalbumin, drugs, substances contained in cosmetics, certain metals used in jewellery or trinkets, such as nickel, insect bites, dust mites, pollen, moulds, pets, and funghi like Aspergillus fumigatus.
• allergens such as substances contained in food, like ovalbumin, drugs, substances contained in cosmetics, certain metals used in jewellery or trinkets, such as nickel, insect bites, dust mites, pollen, moulds, pets, and funghi like Aspergillus fumigatus.
• Figure 1 shows the data on the effectiveness of T ⁇ 1 in ABPA (A) and in allergy from OVA (B). None represents the control mice.
• Figure 2 shows the data on the comparison of the effectiveness of T ⁇ i and CpG in ABPA.
• Figure 3 shows the data on the effect of Tort on pulmonary lymphomonocyte recruitment in ABPA.
• Figure 4 shows the data on the effect of T ⁇ 1 on the local inflammatory pathology in ABPA.
• Example 1 Evaluation of the efficacy of thymosin alpha 1 in two experimental models of allergy.
• a model consists of inducing an allergic state by administering chicken ovalbumin (OVA) in allergising conditions.
• OVA chicken ovalbumin
• the other consists of inducing the allergy from environmental allergens, and namely the spores of the fungus Aspergillus fumigatus.
• mice received 10 7 Aspergillus conidia intratracheal ⁇ (i.t.) for OVA sensibilization.
• mice on day 0, followed by two consecutive intranasal injections (one week apart) of 10 ⁇ g of OVA (chicken OVA grade Vl; Sigma-Aldrich) together with 1 mg of AI(OH) 3 (Alum Inject; Pierce, Rockford, IL) as adjuvant dissolved in a sterile saline solution.
• OVA dry OVA grade Vl; Sigma-Aldrich
• AI(OH) 3 Align; Pierce, Rockford, IL
• the mice were analysed for inflammation and allergy parameters a week later.
• sections from 3 to 4 ⁇ m) of tissues immersed in paraffin were coloured with periodical Schiff acid (PAS) to evaluate the general morphology.
• PAS periodical Schiff acid
• the lung sections coloured with PAS were examined at 50, 200 and 400 enlargements to assess the "Globet" type cells typical of the allergy.
• the differential total and total lung cell counts were carried out by colouring the lung of allergic mice with May-Gr ⁇ nwald reagents (Giemsa Sigma) before the analysis.
• the collagen levels in the lungs were determined as described (Montagnoli C, Fallarino F, Gaziano R, Bozza S, Bellocchio S, Zelante T, Kurup WP, Pitzurra L 1 Puccetti P, Romani L. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J. Immunol. 2006, 176:1712-1723).
• concentrations of hydroxyproline were calculated by means of a standard hydroxyproline curve (zero to 100 ⁇ g/ml).
• IgE determination in the serum was determined by enzyme-linked immunosorbent assay
• T ⁇ 1 purchased from Sigma, St.Louis, MO, USA; product no. T3410; molecular formula C 129 H 215 N 33 O 55
• the scambled peptide were supplied as sterile dried powders.
• the powders were reconstituted in sterile water (endotoxin levels were ⁇ 0,03 pg/ml, by means of standard Limulus lysate assay).
• T ⁇ 1 was administered at a dosage of 50 and 200 microgrammes/kg i.p. according to the design reported in tables 1 and 2, both in the ABPA model and in the allergy from OVA.
• Mice controls received the scrambled peptide.
• the mice were treated for comparison with a known agent that could improve the allergic symptomatology: oligodeoxynucleotide, containing non-methylated CpG (CpG) sequences.
• CpG non-methylated CpG
• Figure 1 shows the data regarding the efficacy of T ⁇ 1 in ABPA
• FIG. 2 shows the comparative data on the effectiveness of T ⁇ 1 and CpG in ABPA.
• the results clearly show a comparable efficacy of T ⁇ 1 with respect to CpG in reducing the allergic inflammation parameters, both in prophylaxis and therapy. None stands for the control mice.
• FIG 3 shows the data on the effect of T ⁇ 1 on pulmonary lymphomonocyte recruitment in ABPA.
• the data show a drastic reduction in the recruitment of eosinophils - the cells responsible for the morbose manifestations of the allergy - by the action of T ⁇ 1 , both in prophylaxis and in therapy.
• the effect was comparable to that of CpG.
• T ⁇ 1 did not have any appreciable effects on the recruitment of other cell typologies, such as neutrophils and monocytes/macrophages.
• Figure 4 shows the data on the effect of T ⁇ 1 on local inflammatory pathology in ABPA.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Zoology (AREA)
• Endocrinology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pulmonology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39322638

Family Applications (1)

Country Status (13)

Cited By (1)

Family Cites Families (4)

• 2006
  • 2006-10-27 IT IT000583A patent/ITRM20060583A1/it unknown
• 2007
  • 2007-09-27 MX MX2009004237A patent/MX2009004237A/es not_active Application Discontinuation
  • 2007-09-27 CA CA002666562A patent/CA2666562A1/en not_active Abandoned
  • 2007-09-27 WO PCT/IT2007/000676 patent/WO2008050362A2/en not_active Ceased
  • 2007-09-27 EP EP07827727A patent/EP2083847A2/en not_active Withdrawn
  • 2007-09-27 EA EA200900603A patent/EA200900603A1/ru unknown
  • 2007-09-27 CN CN200780039959A patent/CN101626778A/zh active Pending
  • 2007-09-27 KR KR1020097008098A patent/KR20090092267A/ko not_active Withdrawn
  • 2007-09-27 AU AU2007310415A patent/AU2007310415A1/en not_active Abandoned
  • 2007-09-27 BR BRPI0718019-5A patent/BRPI0718019A2/pt not_active IP Right Cessation
  • 2007-09-27 US US12/447,156 patent/US20090270594A1/en not_active Abandoned
  • 2007-09-27 JP JP2009534060A patent/JP2010507649A/ja active Pending
• 2009
  • 2009-04-22 IL IL198290A patent/IL198290A0/en unknown

Also Published As

Similar Documents

Legal Events